Callan Family Office LLC Acquires Shares of 3,609 Natera, Inc. $NTRA

Callan Family Office LLC acquired a new stake in Natera, Inc. (NASDAQ:NTRA) during the second quarter, HoldingsChannel reports. The firm acquired 3,609 shares of the medical research company’s stock, valued at approximately $610,000.

Other institutional investors also recently bought and sold shares of the company. Bank of Jackson Hole Trust acquired a new position in shares of Natera during the first quarter worth about $29,000. Rakuten Securities Inc. increased its stake in shares of Natera by 117.8% during the first quarter. Rakuten Securities Inc. now owns 220 shares of the medical research company’s stock worth $31,000 after acquiring an additional 119 shares during the period. ORG Partners LLC acquired a new position in shares of Natera during the first quarter worth about $32,000. TCTC Holdings LLC increased its stake in shares of Natera by 114.8% during the first quarter. TCTC Holdings LLC now owns 232 shares of the medical research company’s stock worth $33,000 after acquiring an additional 124 shares during the period. Finally, Northwestern Mutual Wealth Management Co. increased its stake in shares of Natera by 83.5% during the first quarter. Northwestern Mutual Wealth Management Co. now owns 233 shares of the medical research company’s stock worth $33,000 after acquiring an additional 106 shares during the period. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Natera Price Performance

NTRA stock opened at $174.17 on Tuesday. The company’s 50 day simple moving average is $165.33 and its 200-day simple moving average is $157.54. The firm has a market capitalization of $23.90 billion, a PE ratio of -91.19 and a beta of 1.74. Natera, Inc. has a 12 month low of $117.27 and a 12 month high of $183.00.

Natera (NASDAQ:NTRA) last released its quarterly earnings results on Thursday, August 7th. The medical research company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.14). The business had revenue of $546.60 million during the quarter, compared to analyst estimates of $476.84 million. Natera had a negative net margin of 12.89% and a negative return on equity of 22.22%. The firm’s revenue for the quarter was up 32.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.30) earnings per share. Natera has set its FY 2025 guidance at EPS. As a group, sell-side analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the stock. Evercore ISI upgraded shares of Natera to a “strong-buy” rating and set a $170.00 price target on the stock in a research note on Monday, July 28th. Cowen restated a “buy” rating on shares of Natera in a research report on Friday, August 8th. Wells Fargo & Company initiated coverage on shares of Natera in a research report on Monday, September 22nd. They set an “equal weight” rating and a $175.00 target price on the stock. Morgan Stanley restated an “overweight” rating and set a $195.00 target price on shares of Natera in a research report on Sunday, August 10th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Natera in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $192.88.

Insider Activity

In related news, CFO Michael Burkes Brophy sold 3,045 shares of the company’s stock in a transaction that occurred on Tuesday, July 29th. The shares were sold at an average price of $137.40, for a total transaction of $418,383.00. Following the transaction, the chief financial officer owned 65,430 shares of the company’s stock, valued at approximately $8,990,082. This represents a 4.45% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Rowan E. Chapman sold 2,750 shares of the company’s stock in a transaction that occurred on Thursday, August 28th. The shares were sold at an average price of $166.99, for a total transaction of $459,222.50. Following the transaction, the director directly owned 6,015 shares in the company, valued at $1,004,444.85. The trade was a 31.37% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 72,464 shares of company stock worth $10,963,125. 5.63% of the stock is currently owned by corporate insiders.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.